Glancz Laurence J, Hannan Cathal John, Vyziotis Alexandros, Potter Gillian M, Siripurapu Rekha, Bhalla Raj K, Rutherford Scott A, King Andrew Thomas, Hammerbeck-Ward Charlotte, Crellin Adrian, Pan Shermaine, Colaco Rovel, Whitfield Gillian A, Pathmanaban Omar N
Department of Neurosurgery, Queens Medical Centre, Manchester, UK.
School of Medicine, University of Nottingham, Nottingham, UK.
BMJ Oncol. 2024 Jul 29;3(1):e000386. doi: 10.1136/bmjonc-2024-000386. eCollection 2024.
Skull base chordoma and chondrosarcoma are distinct sarcomas of the skull base but share significant therapeutic challenges due to their proximity to critical neurovascular structures, making surgical resection difficult. We sought to establish factors associated with outcome predictors in a national cohort of patients.
Data for all patients referred with a diagnosis of skull base chordoma or chondrosarcoma from April 2017 to December 2022 were obtained. We performed analyses of data pertaining to the first cohort of patients treated in the UK with proton beam therapy (PBT) to determine factors associated with obtaining gross total resection (GTR) and adequate clearance of the brainstem and optic apparatus.
Of 230 patients with skull base chordoma or chondrosarcoma referred for PBT, 71% were accepted for PBT, with a wide regional variation between referring neurosurgical units (29%-93%). Of the first 75 consecutive patients treated with PBT, the only factor predictive of obtaining GTR was surgical resection at a unit with higher volumes of patients accepted for PBT (OR 1.32, 95% CI 1.11 to 1.63, p=0.004). Use of intraoperative MRI (OR 4.84, 95% CI 1.21 to 27.83, p=0.04) and resection at a higher volume unit (OR 1.29, 95% CI 1.07 to 1.64, p=0.013) were associated with increased rates of tumour clearance from the brainstem/optic apparatus.
Treatment at a higher volume centre was a key determinant of the optimal surgical outcome in this cohort. These data support the management of skull base chordomas and chondrosarcomas in higher volume centres where multidisciplinary experience can be accumulated.
颅底脊索瘤和软骨肉瘤是颅底不同的肉瘤,但由于它们靠近关键神经血管结构,手术切除困难,因此面临重大治疗挑战。我们试图在全国患者队列中确定与预后预测因素相关的因素。
获取了2017年4月至2022年12月期间所有被诊断为颅底脊索瘤或软骨肉瘤患者的数据。我们对英国首批接受质子束治疗(PBT)的患者队列数据进行分析,以确定与实现肿瘤全切除(GTR)以及脑干和视器充分清除相关的因素。
在230例转诊接受PBT的颅底脊索瘤或软骨肉瘤患者中,71%被接受PBT治疗,转诊神经外科单位之间存在较大的地区差异(29%-93%)。在首批连续接受PBT治疗的75例患者中,唯一预测能实现GTR的因素是在接受PBT患者数量较多的单位进行手术切除(比值比1.32,95%置信区间1.11至1.63,p=0.004)。术中磁共振成像的使用(比值比4.84,95%置信区间1.21至27.83,p=0.04)以及在患者数量较多的单位进行切除(比值比1.29,95%置信区间1.07至1.64,p=0.013)与脑干/视器肿瘤清除率增加相关。
在患者数量较多的中心进行治疗是该队列中最佳手术结果的关键决定因素。这些数据支持在能够积累多学科经验的患者数量较多的中心对颅底脊索瘤和软骨肉瘤进行管理。